Literature DB >> 23647953

Virus-neutralizing antibodies to hepatitis C virus.

A Wahid1, J Dubuisson.   

Abstract

For a long time, the lack of an appropriate cell culture system has hampered the study of neutralizing antibody responses against hepatitis C virus (HCV). However, the last decade has seen the development of several model systems that have significantly advanced our understanding of viral entry and antibody neutralization. Studies of acutely infected patients suggest that a strong and early production of neutralizing antibodies may contribute to control the virus during the acute phase of HCV infection and facilitate viral elimination by cellular immune responses. It also emerges that the early antibody response mainly targets hypervariable region 1 (HVR1) of the envelope glycoprotein E2. This host response can lead to viral escape from neutralization by rapid amino acid changes in this hypervariable region. In contrast, cross-reactive neutralizing antibodies seem to appear later during HCV infection, and several mechanisms contribute to reduce their accessibility to their cognate epitopes. These include the masking of major conserved neutralizing epitopes by HVR1, specific N-linked glycans and the lipid moiety of the viral particle. Other potential mechanisms of evasion from the neutralizing antibody response include a modulation by high-density lipoproteins and interfering antibodies as well as the capacity of the virus to be transferred by cell-to-cell contacts. Finally, the recent identification of several highly conserved neutralizing epitopes provides some opportunities for the design and development of vaccine candidates that elicit a protective humoral immune response.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23647953     DOI: 10.1111/jvh.12094

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  35 in total

1.  Viral hepatitis: Cell-culture-derived HCV--a promising vaccine antigen.

Authors:  Judith M Gottwein; Jens Bukh
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-07-30       Impact factor: 46.802

2.  Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity.

Authors:  Jannick Prentoe; Rodrigo Velázquez-Moctezuma; Steven K H Foung; Mansun Law; Jens Bukh
Journal:  Hepatology       Date:  2016-08-09       Impact factor: 17.425

3.  Oligonucleotide-Lipid Conjugates Forming G-Quadruplex Structures Are Potent and Pangenotypic Hepatitis C Virus Entry Inhibitors In Vitro and Ex Vivo.

Authors:  George Koutsoudakis; Alexia Paris de León; Carolina Herrera; Marcus Dorner; Gemma Pérez-Vilaró; Sébastien Lyonnais; Santiago Grijalvo; Ramon Eritja; Andreas Meyerhans; Gilles Mirambeau; Juana Díez
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 4.  Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design.

Authors:  Leopold Kong; Kelli N Jackson; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2015-04-29       Impact factor: 7.090

Review 5.  Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals.

Authors:  Jacinta A Holmes; Ming-Lung Yu; Raymond T Chung
Journal:  Expert Opin Drug Saf       Date:  2017-05-19       Impact factor: 4.250

6.  Non-neutralizing epitopes induce robust hepatitis C virus (HCV)-specific antibody-dependent CD56+ natural killer cell responses in chronic HCV-infected patients.

Authors:  L Long; M Jia; X Fan; H Liang; J Wang; L Zhu; Z Xie; T Shen
Journal:  Clin Exp Immunol       Date:  2017-04-07       Impact factor: 4.330

Review 7.  The ins and outs of hepatitis C virus entry and assembly.

Authors:  Brett D Lindenbach; Charles M Rice
Journal:  Nat Rev Microbiol       Date:  2013-09-10       Impact factor: 60.633

8.  Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.

Authors:  Thibaut Vausselin; Karin Séron; Muriel Lavie; Ahmed Atef Mesalam; Matthieu Lemasson; Sandrine Belouzard; Lucie Fénéant; Adeline Danneels; Yves Rouillé; Laurence Cocquerel; Lander Foquet; Arielle R Rosenberg; Czeslaw Wychowski; Philip Meuleman; Patricia Melnyk; Jean Dubuisson
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

Review 9.  Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees.

Authors:  Babs E Verstrepen; André Boonstra; Gerrit Koopman
Journal:  World J Hepatol       Date:  2015-01-27

Review 10.  Hepatitis C.

Authors:  Daniel P Webster; Paul Klenerman; Geoffrey M Dusheiko
Journal:  Lancet       Date:  2015-02-14       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.